CCM
MRSN

Catalio Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Catalio Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,697
Closed -$464K – 44
2025
Q2 		$464K Sell
62,697
-5,504
-8% -$48.4K 0.1% 37
2025
Q1 		$587K Hold
68,201
– – 0.14% 31
2024
Q4 		$2.44M Buy
+68,201
New +$3.53M 0.53% 25

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Catalio Capital Management's MRSN Position: Q3 2025 in Review

Catalio Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 62,697 shares — an estimated $464K sold.

Catalio Capital Management first reported a position in MRSN in Q4 2024 and held it in 3 quarters. The position peaked at $2.44M in Q4 2024. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Catalio Capital Management reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 62,697 Mersana Therapeutics shares in Q3 2025, an estimated $464K.
  • Catalio Capital Management first reported a position in Mersana Therapeutics in Q4 2024 and held it in 3 quarters.
  • Catalio Capital Management's Mersana Therapeutics position peaked at $2.44M in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.